4.5800 +0.04 (0.88%)
After hours: 6:24PM EDT
|Bid||4.4800 x 800|
|Ask||4.5800 x 800|
|Day's range||4.2800 - 4.5800|
|52-week range||2.1700 - 9.6980|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||N/A|
|Earnings date||30 Jul 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.20|
Investors need to pay close attention to InflaRx (IFRX) stock based on the movements in the options market lately.
InflaRx has been struggling lately, but the selling pressure may be coming to an end soon.
InflaRx (IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today interim results from the first 30 patients treated in the adaptive randomized Phase II/III trial in patients with severe COVID-19 pneumonia. The Phase II part of the study evaluated IFX-1 treatment plus best supportive care compared to best supportive care alone for up to 28 days. Relative change (%) from baseline to day 5 in oxygenation index (defined as PaO2/FiO2 ratio) was assessed as the primary endpoint along with additional clinical parameters until day 28.